Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05002270 · ClinicalTrials.gov registry record · Phase 1
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Jacobio Pharmaceuticals Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 4
- Study locations
NCT05002270: Completed Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Jacobio Pharmaceuticals Co..
NCT05002270 is a Phase 1 study of Advanced Solid Tumor and NSCLC that has completed, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 29 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05002270, a Phase 1 study of Advanced Solid Tumor and NSCLC, has completed, sponsored by Jacobio Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
Conditions Studied
Interventions
- DRUG JAB-21822 (KRAS G12C inhibitor)
- DRUG Cetuximab (EGFR inhibitor)
Study Locations (4)
Arizona
- Mayo Clinc - Phoenix
- Mayo Clinc - Scottsdale
Florida
- Mayo Clinc - Jacksonville
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 1 |
What the finished NCT05002270 record still lists
NCT05002270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which JAB-21822 (KRAS G12C inhibitor) is the first listed.
NCT05002270 reports a single indexed study location in Arizona, Florida, Utah.
Frequently Asked Questions
What is clinical trial NCT05002270 about?
NCT05002270 is a clinical study titled "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation". This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
What is the current status of trial NCT05002270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-09-03. Estimated completion is 2025-02-12.
What conditions does trial NCT05002270 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC, CRC.
What interventions are being tested in trial NCT05002270?
The interventions under investigation include: JAB-21822 (KRAS G12C inhibitor) (DRUG), Cetuximab (EGFR inhibitor) (DRUG).
Who is sponsoring clinical trial NCT05002270?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05002270 being conducted?
This trial has 4 study locations across Arizona, Florida, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05002270's enrollment target sits among peer trials
29 177th of 189 higher than 13 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI